首页 > 最新文献

Best practice & research. Clinical endocrinology & metabolism最新文献

英文 中文
Developments in interventional management of hepatic metastases from neuroendocrine tumours 神经内分泌肿瘤肝转移的介入治疗进展。
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 DOI: 10.1016/j.beem.2023.101798
Ashley Kieran Clift (Clinical Research Fellow) , Robert Thomas (Consultant Diagnostic and Interventional Radiologist) , Andrea Frilling (Chair in Endocrine Surgery)

Neuroendocrine tumours commonly metastasise to the liver, particularly those arising from the intestinal tract and pancreas. Whilst surgery offers the only approach with intent to cure, the vast majority of patients with neuroendocrine liver metastases are ineligible. Liver-directed interventional therapies seek to exploit the patho-anatomy of the blood supply of hepatic metastases to deliver therapy to liver deposits. This may involve percutaneous ablation, bland embolization, or the selective infusion of chemotherapeutics, targeted agents or radiolabelled embolic material. Retrospective case series evidence has characterised objective response rates, disease control rates, and longer-term outcomes associated with each approach. Recent advances in this field include ongoing comparative trials of different techniques, but more importantly, combinations of interventional liver-directed therapies and other systemic therapy in multimodal treatment concepts.

神经内分泌肿瘤通常转移到肝脏,尤其是那些来自肠道和胰腺的肿瘤。虽然手术是唯一有治愈意图的方法,但绝大多数神经内分泌肝转移患者都不符合条件。肝导向介入治疗寻求利用肝转移血供的病理解剖结构来对肝脏沉积物进行治疗。这可能涉及经皮消融、轻度栓塞或选择性输注化疗药物、靶向药物或放射性标记的栓塞材料。回顾性病例系列证据具有客观反应率、疾病控制率和与每种方法相关的长期结果的特征。该领域的最新进展包括正在进行的不同技术的比较试验,但更重要的是,在多模式治疗概念中,介入性肝导向治疗和其他全身治疗的组合。
{"title":"Developments in interventional management of hepatic metastases from neuroendocrine tumours","authors":"Ashley Kieran Clift (Clinical Research Fellow) ,&nbsp;Robert Thomas (Consultant Diagnostic and Interventional Radiologist) ,&nbsp;Andrea Frilling (Chair in Endocrine Surgery)","doi":"10.1016/j.beem.2023.101798","DOIUrl":"10.1016/j.beem.2023.101798","url":null,"abstract":"<div><p>Neuroendocrine tumours commonly metastasise to the liver, particularly those arising from the intestinal tract and pancreas. Whilst surgery offers the only approach with intent to cure, the vast majority of patients with neuroendocrine liver metastases are ineligible. Liver-directed interventional therapies seek to exploit the patho-anatomy of the blood supply of hepatic metastases to deliver therapy to liver deposits. This may involve percutaneous ablation, bland embolization, or the selective infusion of chemotherapeutics, targeted agents or radiolabelled embolic material. Retrospective case series evidence has characterised objective response rates, disease control rates, and longer-term outcomes associated with each approach. Recent advances in this field include ongoing comparative trials of different techniques, but more importantly, combinations of interventional liver-directed therapies and other systemic therapy in multimodal treatment concepts.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 5","pages":"Article 101798"},"PeriodicalIF":7.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9834725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence? 选择控制胃肠胰神经内分泌肿瘤(GEP-NETs)肿瘤生长的最佳全身治疗序列:最近的证据是什么?
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 DOI: 10.1016/j.beem.2023.101836
Maria Passhak (Consultant in Clinical Oncology) , Mairéad G. McNamara (Senior Lecturer and Consultant in Medical Oncology) , Richard A. Hubner (Consultant in Medical Oncology) , Irit Ben-Aharon (Professor in Oncology) , Juan W. Valle (Professor in Medical Oncology)

Gastro-enteropancreatic neuroendocrine tumours (GEP-NETs) represent a rare and highly heterogeneous entity with increasing incidence. Based on the results obtained from several trials performed in the last decade, various therapeutic options have been established for the treatment of patients with GEP-NETs. The options include somatostatin analogues, targeted therapies (sunitinib and everolimus), chemotherapy (with temozolomide or streptozocin-based regimens), and peptide receptor radionuclide therapy. The treatment choice is influenced by various clinico-pathological factors including tumour grade and morphology, the primary mass location, hormone secretion, the volume of the disease and the rate of tumour growth, as well as patient comorbidities and performance status. In this review, the efficacy and safety of treatment options for patients with GEP-NETs is discussed and the evidence to inform the best sequence of available therapies to control tumour growth, prolong patient survival, and to lower potential toxicity, while maintaining patient quality of life is explored.

胃肠胰腺神经内分泌肿瘤(GEP-NETs)是一种罕见且高度异质性的肿瘤,发病率不断增加。根据过去十年中进行的几项试验的结果,已经为GEP-NETs患者的治疗制定了各种治疗方案。选择包括生长抑素类似物、靶向治疗(舒尼替尼和依维莫司)、化疗(以替莫唑胺或链脲佐菌素为基础的方案)和肽受体放射性核素治疗。治疗选择受到各种临床病理因素的影响,包括肿瘤分级和形态、主要肿块位置、激素分泌、疾病体积和肿瘤生长速度,以及患者合并症和表现状态。在这篇综述中,讨论了GEP-NETs患者治疗方案的有效性和安全性,并探讨了在保持患者生活质量的同时,为控制肿瘤生长、延长患者生存期和降低潜在毒性提供最佳治疗顺序的证据。
{"title":"Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?","authors":"Maria Passhak (Consultant in Clinical Oncology) ,&nbsp;Mairéad G. McNamara (Senior Lecturer and Consultant in Medical Oncology) ,&nbsp;Richard A. Hubner (Consultant in Medical Oncology) ,&nbsp;Irit Ben-Aharon (Professor in Oncology) ,&nbsp;Juan W. Valle (Professor in Medical Oncology)","doi":"10.1016/j.beem.2023.101836","DOIUrl":"10.1016/j.beem.2023.101836","url":null,"abstract":"<div><p>Gastro-enteropancreatic neuroendocrine tumours (GEP-NETs) represent a rare and highly heterogeneous entity with increasing incidence. Based on the results obtained from several trials performed in the last decade, various therapeutic options have been established for the treatment of patients with GEP-NETs. The options include somatostatin analogues, targeted therapies (sunitinib and everolimus), chemotherapy (with temozolomide or streptozocin-based regimens), and peptide receptor radionuclide therapy. The treatment choice is influenced by various clinico-pathological factors including tumour grade and morphology, the primary mass location, hormone secretion, the volume of the disease and the rate of tumour growth, as well as patient comorbidities and performance status. In this review, the efficacy and safety of treatment options for patients with GEP-NETs is discussed and the evidence to inform the best sequence of available therapies to control tumour growth, prolong patient survival, and to lower potential toxicity, while maintaining patient quality of life is explored.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 5","pages":"Article 101836"},"PeriodicalIF":7.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023? 胃肠胰神经内分泌肿瘤的精准医疗:2023年我们在哪里?
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 DOI: 10.1016/j.beem.2023.101794
Nicola Fazio (Oncologist, Director of Program in Digestive System and Neuroendocrine Tumors) , Anna La Salvia (Oncologist, Researcher)

Precision medicine describes a target-related approach to tailoring diagnosis and treatment of the individual patient. While this personalized approach is revoluzionizing many areas of oncology, it is quite late in the field of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), in which there are few molecular alterations to be therapeutically targeted. We critically reviewed the current evidence about precision medicine in GEP NENs, focusing on potential clinically relevant actionable targets for GEP NENs, such as the mTOR pathway, MGMT, hypoxia markers, RET, DLL-3, and some general agnostic targets. We analysed the main investigational approaches with solid and liquid biopsies. Furthermore, we reviewed a model of precision medicine more specific for NENs that is the theragnostic use of radionuclides. Overall, currently no true predictive factors for therapy have been validated so far in GEP NENs, and the personalized approach is based more on clinical thinking within a NEN-dedicated multidisciplinary team. However, there is a robust background to suppose that precision medicine, with the theragnostic model will yield new insights in this context soon.

精准医学描述了一种与目标相关的方法来定制个体患者的诊断和治疗。虽然这种个性化的方法正在改变肿瘤学的许多领域,但在胃肠胰神经内分泌肿瘤(GEP-NENs)领域已经相当晚了,在该领域几乎没有可作为治疗靶点的分子改变。我们批判性地回顾了目前关于GEP-NEN精准医学的证据,重点关注GEP-NENs潜在的临床相关可操作靶点,如mTOR途径、MGMT、缺氧标志物、RET、DLL-3和一些一般不可知靶点。我们分析了固体和液体活检的主要研究方法。此外,我们还回顾了一种更专门针对NEN的精确医学模型,即放射性核素的诊断用途。总体而言,到目前为止,GEP NEN还没有验证治疗的真正预测因素,个性化方法更多地基于NEN专门的多学科团队的临床思维。然而,有一个强有力的背景可以假设,精准医学和灵药模型将很快在这方面产生新的见解。
{"title":"Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?","authors":"Nicola Fazio (Oncologist, Director of Program in Digestive System and Neuroendocrine Tumors) ,&nbsp;Anna La Salvia (Oncologist, Researcher)","doi":"10.1016/j.beem.2023.101794","DOIUrl":"10.1016/j.beem.2023.101794","url":null,"abstract":"<div><p><em>Precision medicine</em><span><span> describes a target-related approach to tailoring diagnosis and treatment of the individual patient. While this personalized approach is revoluzionizing many areas of </span>oncology, it is quite late in the field of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), in which there are few molecular alterations to be therapeutically targeted. We critically reviewed the current evidence about </span><em>precision medicine</em><span><span> in GEP NENs, focusing on potential clinically relevant actionable targets for GEP NENs, such as the mTOR pathway, </span>MGMT<span><span>, hypoxia<span><span> markers, RET, DLL-3, and some general agnostic targets. We analysed the main investigational approaches with solid and liquid biopsies. Furthermore, we reviewed a model of precision medicine more specific for NENs that is the theragnostic use of </span>radionuclides. Overall, currently no true </span></span>predictive factors for therapy have been validated so far in GEP NENs, and the personalized approach is based more on clinical thinking within a NEN-dedicated multidisciplinary team. However, there is a robust background to suppose that precision medicine, with the theragnostic model will yield new insights in this context soon.</span></span></p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 5","pages":"Article 101794"},"PeriodicalIF":7.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9749487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms 有效控制功能神经内分泌肿瘤激素分泌的策略。
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 DOI: 10.1016/j.beem.2023.101787
Johannes Hofland (Consultant Endocrinologist), Wouter W. de Herder (Consultant Endocrinologist)

Neuroendocrine neoplasms are a unique form of malignancies as they can be accompanied by specific functioning hormonal syndromes that can impair survival and quality of life in patients. Functioning syndromes are defined by the combination of specific clinical signs and symptoms in combination with inappropriately elevated circulating levels of hormones. Clinicians should remain vigilant for the presence of functioning syndromes in neuroendocrine neoplasm patients at presentation as well as during follow-up. The correct diagnostic work-up should be initiated in cases of clinical suspicion of a neuroendocrine neoplasm-associated functioning syndrome. Management of a functional syndrome includes options from supportive, surgical, hormonal and antiproliferative treatment modalities. Here, we review the patient and tumour characteristics for each functioning syndrome that should be taken into account when deciding the optimum treatment strategy in neuroendocrine neoplasm patients.

神经内分泌肿瘤是一种独特的恶性肿瘤,因为它们可能伴有特定的功能性激素综合征,从而损害患者的生存和生活质量。功能综合征是指特定的临床体征和症状与激素循环水平不适当升高相结合。临床医生应在神经内分泌肿瘤患者就诊时和随访期间对其功能综合征的存在保持警惕。在临床怀疑神经内分泌肿瘤相关功能综合征的情况下,应开始正确的诊断检查。功能性综合征的治疗包括支持性治疗、手术治疗、激素治疗和抗增殖治疗。在此,我们回顾了神经内分泌肿瘤患者在决定最佳治疗策略时应考虑的每种功能综合征的患者和肿瘤特征。
{"title":"Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms","authors":"Johannes Hofland (Consultant Endocrinologist),&nbsp;Wouter W. de Herder (Consultant Endocrinologist)","doi":"10.1016/j.beem.2023.101787","DOIUrl":"10.1016/j.beem.2023.101787","url":null,"abstract":"<div><p>Neuroendocrine neoplasms are a unique form of malignancies as they can be accompanied by specific functioning hormonal syndromes that can impair survival and quality of life in patients. Functioning syndromes are defined by the combination of specific clinical signs and symptoms in combination with inappropriately elevated circulating levels of hormones. Clinicians should remain vigilant for the presence of functioning syndromes in neuroendocrine neoplasm patients at presentation as well as during follow-up. The correct diagnostic work-up should be initiated in cases of clinical suspicion of a neuroendocrine neoplasm-associated functioning syndrome. Management of a functional syndrome includes options from supportive, surgical, hormonal and antiproliferative treatment modalities. Here, we review the patient and tumour characteristics for each functioning syndrome that should be taken into account when deciding the optimum treatment strategy in neuroendocrine neoplasm patients.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 5","pages":"Article 101787"},"PeriodicalIF":7.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9626513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know 消化神经内分泌肿瘤的组织病理学分类和组织生物标志物的最新进展:临床医生应该知道的。
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 DOI: 10.1016/j.beem.2023.101795
Anne Couvelard (Pathologist) , Aurélie Cazes Pathologist , Jérôme Cros (Pathologist)

Histopathological classifications of neuroendocrine neoplasms (NEN) change regularly and the latest WHO classification published in 2022, which concerns all NEN in the body, attempts to standardize classifications in the different locations. Differentiation and proliferation mainly assessed by Ki-67 index are still the cornerstone of those classifications. However, many markers are now used for diagnostic (to check neuroendocrine differentiation, to identify the site of origin of a metastasis, to help separating high-grade neuroendocrine tumors/NET and neuroendocrine carcinoma/NEC), prognostic or theranostic purposes. NENs are often heterogeneous and this can lead to difficulties in classifications, biomarker and prognostic assessment. These different points are discussed successively in this review, insisting especially on the frequent digestive, gastro-entero-pancreatic (GEP) localizations.

神经内分泌肿瘤(NEN)的组织病理学分类定期变化,2022年发布的最新世界卫生组织分类涉及体内所有NEN,试图将不同位置的分类标准化。主要通过Ki-67指数评估分化和增殖仍然是这些分类的基石。然而,许多标志物现在被用于诊断(检查神经内分泌分化,确定转移的起源部位,帮助分离高级神经内分泌肿瘤/NET和神经内分泌癌/NEC)、预后或治疗目的。NEN通常是异质性的,这可能导致分类、生物标志物和预后评估方面的困难。在这篇综述中,我们对这些不同的观点进行了连续的讨论,特别强调了常见的消化、胃肠-胰腺(GEP)定位。
{"title":"Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know","authors":"Anne Couvelard (Pathologist) ,&nbsp;Aurélie Cazes Pathologist ,&nbsp;Jérôme Cros (Pathologist)","doi":"10.1016/j.beem.2023.101795","DOIUrl":"10.1016/j.beem.2023.101795","url":null,"abstract":"<div><p><span>Histopathological classifications of neuroendocrine neoplasms (NEN) change regularly and the latest WHO classification published in 2022, which concerns all NEN in the body, attempts to standardize classifications in the different locations. Differentiation and proliferation mainly assessed by Ki-67 index are still the cornerstone of those classifications. However, many markers are now used for diagnostic (to check neuroendocrine differentiation<span>, to identify the site of origin of a metastasis, to help separating high-grade neuroendocrine tumors/NET and neuroendocrine carcinoma/NEC), prognostic or theranostic purposes. NENs are often heterogeneous and this can lead to difficulties in classifications, biomarker and </span></span>prognostic assessment. These different points are discussed successively in this review, insisting especially on the frequent digestive, gastro-entero-pancreatic (GEP) localizations.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 5","pages":"Article 101795"},"PeriodicalIF":7.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New horizon of radiopharmaceuticals in management of neuroendocrine tumors 放射性药物治疗神经内分泌肿瘤的新进展。
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 DOI: 10.1016/j.beem.2023.101797
Adeel Haq (Fellow Nuclear Medicine), Sampanna Rayamajhi (Fellow Nuclear Medicine), Maria Rosana Ponisio (Assoc Prof of Radiology), Vikas Prasad (Assoc Prof of Radiology)

Neuroendocrine neoplasms are rare and heterogenous group of tumors with varying degrees of clinical presentations and involvement of multiple organ systems in the body. In the modern clinical practice somatostatin receptor molecular imaging and targeted radioligand therapy plays a vital role in the diagnosis and management of the disease. Several new and promising radiotracers for NET imaging and theranostics, belonging to various groups and classes are being studied and investigated. This exponential growth of radiotracers poses concerns about the indication, clinical benefit, and safety profile of the agents. We discuss the basis behind these radiotracers clinical use, receptor targeting and intra and inter tumor heterogeneity. Furthermore, role of dual tracer imaging, combination therapy and potential applications of dosimetry in predicting treatment outcome and safety profile is reviewed. Individualized precision medicine with better tumor characterization, maximum therapeutic benefit and minimum toxicity is the way forward for future medicine.

神经内分泌肿瘤是一组罕见的异质性肿瘤,具有不同程度的临床表现和全身多器官系统的受累。在现代临床实践中,生长抑素受体分子成像和靶向放射性配体治疗在疾病的诊断和治疗中起着至关重要的作用。目前正在研究和研究几种新的、有前景的用于NET成像和治疗的放射性示踪剂,它们属于不同的组和类别。放射性示踪剂的这种指数增长引起了对药物适应症、临床益处和安全性的担忧。我们讨论了这些放射性示踪剂临床应用、受体靶向以及肿瘤内和肿瘤间异质性背后的基础。此外,还综述了双示踪剂成像、联合治疗以及剂量测定在预测治疗结果和安全性方面的潜在应用。具有更好的肿瘤特征、最大的治疗效益和最小的毒性的个性化精准医学是未来医学的发展方向。
{"title":"New horizon of radiopharmaceuticals in management of neuroendocrine tumors","authors":"Adeel Haq (Fellow Nuclear Medicine),&nbsp;Sampanna Rayamajhi (Fellow Nuclear Medicine),&nbsp;Maria Rosana Ponisio (Assoc Prof of Radiology),&nbsp;Vikas Prasad (Assoc Prof of Radiology)","doi":"10.1016/j.beem.2023.101797","DOIUrl":"10.1016/j.beem.2023.101797","url":null,"abstract":"<div><p><span>Neuroendocrine neoplasms are rare and heterogenous group of tumors with varying degrees of clinical presentations and involvement of multiple organ systems in the body. In the modern clinical practice somatostatin receptor </span>molecular imaging<span><span><span> and targeted radioligand therapy plays a vital role in the diagnosis and management of the disease. Several new and promising </span>radiotracers<span> for NET imaging and theranostics, belonging to various groups and classes are being studied and investigated. This exponential growth of radiotracers poses concerns about the indication, clinical benefit, and safety profile of the agents. We discuss the basis behind these radiotracers clinical use, receptor targeting and intra and inter tumor heterogeneity. Furthermore, role of dual tracer imaging, combination therapy and potential applications of </span></span>dosimetry<span> in predicting treatment outcome and safety profile is reviewed. Individualized precision medicine with better tumor characterization, maximum therapeutic benefit and minimum toxicity is the way forward for future medicine.</span></span></p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 5","pages":"Article 101797"},"PeriodicalIF":7.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9834720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of non-hepatic distant metastases in neuroendocrine neoplasms 神经内分泌肿瘤非肝远处转移的处理。
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 DOI: 10.1016/j.beem.2023.101784
C. Lacalle-González (Medical Oncologist) , A. Estrella Santos (Endocrinologist) , L.C. Landaeta Kancev (Nuclear Medicine Physician) , V.M. Castellano (Pathologist) , E. Macia Palafox (Cardiologist) , A. Paniagua Ruíz (Endocrinologist) , J. Luna Tirado (Radiation Oncologist) , B. Martínez-Amores (Medical Oncologist) , L. Martínez Dhier (Nuclear Medicine Physician) , A. Lamarca (Medical Oncologist)

Neuroendocrine neoplasms represent an uncommon disease with an increasing incidence. Thanks to improvements in diagnostic and therapeutic methods, metastases previously considered uncommon, such as bone metastases, or even very rare, such as brain, orbital and cardiac metastases, are more frequently found in daily practice. Due to the great heterogeneity of these neoplasms, there is a lack of high-quality evidence on the management of patients with these types of metastases. The aim of this review is to provide the current state of the art, reviewing neuroendocrine neoplasm specific studies and useful information from other tumor types and to propose a treatment recommendation with algorithms to consider in daily clinical practice.

神经内分泌肿瘤是一种发病率不断上升的罕见疾病。由于诊断和治疗方法的改进,以前被认为不常见的转移,如骨转移,甚至非常罕见的转移,例如脑、眼眶和心脏转移,在日常实践中更常见。由于这些肿瘤的高度异质性,缺乏关于这些类型转移患者治疗的高质量证据。本综述的目的是提供最新技术,回顾神经内分泌肿瘤特异性研究和其他肿瘤类型的有用信息,并提出治疗建议和算法,供日常临床实践考虑。
{"title":"Management of non-hepatic distant metastases in neuroendocrine neoplasms","authors":"C. Lacalle-González (Medical Oncologist) ,&nbsp;A. Estrella Santos (Endocrinologist) ,&nbsp;L.C. Landaeta Kancev (Nuclear Medicine Physician) ,&nbsp;V.M. Castellano (Pathologist) ,&nbsp;E. Macia Palafox (Cardiologist) ,&nbsp;A. Paniagua Ruíz (Endocrinologist) ,&nbsp;J. Luna Tirado (Radiation Oncologist) ,&nbsp;B. Martínez-Amores (Medical Oncologist) ,&nbsp;L. Martínez Dhier (Nuclear Medicine Physician) ,&nbsp;A. Lamarca (Medical Oncologist)","doi":"10.1016/j.beem.2023.101784","DOIUrl":"10.1016/j.beem.2023.101784","url":null,"abstract":"<div><p><span>Neuroendocrine neoplasms represent an uncommon disease with an increasing incidence. Thanks to improvements in diagnostic and therapeutic methods, metastases previously considered uncommon, such as </span>bone metastases<span>, or even very rare, such as brain, orbital and cardiac metastases, are more frequently found in daily practice. Due to the great heterogeneity of these neoplasms, there is a lack of high-quality evidence on the management of patients with these types of metastases. The aim of this review is to provide the current state of the art, reviewing neuroendocrine neoplasm specific studies and useful information from other tumor types and to propose a treatment recommendation with algorithms to consider in daily clinical practice.</span></p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 5","pages":"Article 101784"},"PeriodicalIF":7.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9569430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors 形态学成像在评估神经内分泌肿瘤治疗反应和疾病进展中的适当应用。
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 DOI: 10.1016/j.beem.2023.101827
Maxime Ronot (Radiologist) , Marco Dioguardi Burgio (Radiologist) , Jules Gregory (Radiologist) , Olivia Hentic (Pancreatologist) , Marie-Pierre Vullierme (Radiologist) , Philippe Ruszniewski (Pancreatologist) , Magaly Zappa (Radiologist) , Louis de Mestier (Pancreatologist)

Neuroendocrine tumors (NETs) are relatively rare neoplasms displaying heterogeneous clinical behavior, ranging from indolent to aggressive forms. Patients diagnosed with NETs usually receive a varied array of treatments, including somatostatin analogs, locoregional treatments (ablation, intra-arterial therapy), cytotoxic chemotherapy, peptide receptor radionuclide therapy (PRRT), and targeted therapies. To maximize therapeutic efficacy while limiting toxicity (both physical and economic), there is a need for accurate and reliable tools to monitor disease evolution and progression and to assess the effectiveness of these treatments. Imaging morphological methods, primarily relying on computed tomography (CT) and magnetic resonance imaging (MRI), are indispensable modalities for the initial evaluation and continuous monitoring of patients with NETs, therefore playing a pivotal role in gauging the response to treatment. The primary goal of assessing tumor response is to anticipate and weigh the benefits of treatments, especially in terms of survival gain. The World Health Organization took the pioneering step of introducing assessment criteria based on cross-sectional imaging. This initial proposal standardized the measurement of lesion sizes, laying the groundwork for subsequent criteria. The Response Evaluation Criteria in Solid Tumors (RECIST) subsequently refined and enhanced these standards, swiftly gaining acceptance within the oncology community. New treatments were progressively introduced, targeting specific features of NETs (such as tumor vascularization or expression of specific receptors), and achieving significant qualitative changes within tumors, although associated with minimal or paradoxical effects on tumor size. Several alternative criteria, adapted from those used in other cancer types and focusing on tumor viability, the slow growth of NETs, or refining the existing size-based RECIST criteria, have been proposed in NETs. This review article aims to describe and discuss the optimal utilization of CT and MRI for assessing the response of NETs to treatment; it provides a comprehensive overview of established and emerging criteria for evaluating tumor response, along with comparative analyses. Molecular imaging will not be addressed here and is covered in a dedicated article within this special issue.

神经内分泌肿瘤(NETs)是一种相对罕见的肿瘤,表现出不同的临床行为,从惰性到侵袭性。被诊断为NETs的患者通常接受各种治疗,包括生长抑素类似物、局部治疗(消融、动脉内治疗)、细胞毒性化疗、肽受体放射性核素治疗(PRRT)和靶向治疗。为了最大限度地提高治疗效果,同时限制毒性(物理和经济),需要准确可靠的工具来监测疾病的演变和进展,并评估这些治疗的有效性。主要依靠计算机断层扫描(CT)和磁共振成像(MRI)的成像形态学方法是对NETs患者进行初步评估和持续监测的不可或缺的模式,因此在衡量治疗反应方面发挥着关键作用。评估肿瘤反应的主要目标是预测和权衡治疗的益处,尤其是在生存率方面。世界卫生组织率先引入了基于横断面成像的评估标准。这项最初的提案标准化了病变大小的测量,为随后的标准奠定了基础。实体瘤反应评估标准(RECIST)随后完善并增强了这些标准,迅速获得肿瘤学界的认可。新的治疗方法被逐步引入,靶向NETs的特定特征(如肿瘤血管形成或特定受体的表达),并在肿瘤内实现了显著的质量变化,尽管对肿瘤大小的影响很小或自相矛盾。在NETs中提出了几种替代标准,这些标准适用于其他癌症类型,并侧重于肿瘤生存能力、NETs的缓慢生长或完善现有的基于大小的RECIST标准。这篇综述文章旨在描述和讨论CT和MRI在评估NETs对治疗的反应方面的最佳利用;它提供了一个已建立和新出现的评估肿瘤反应的标准的全面概述,以及比较分析。分子成像将不在这里讨论,并在本特刊的一篇专门文章中介绍。
{"title":"Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors","authors":"Maxime Ronot (Radiologist) ,&nbsp;Marco Dioguardi Burgio (Radiologist) ,&nbsp;Jules Gregory (Radiologist) ,&nbsp;Olivia Hentic (Pancreatologist) ,&nbsp;Marie-Pierre Vullierme (Radiologist) ,&nbsp;Philippe Ruszniewski (Pancreatologist) ,&nbsp;Magaly Zappa (Radiologist) ,&nbsp;Louis de Mestier (Pancreatologist)","doi":"10.1016/j.beem.2023.101827","DOIUrl":"10.1016/j.beem.2023.101827","url":null,"abstract":"<div><p><span><span><span>Neuroendocrine tumors (NETs) are relatively rare neoplasms displaying heterogeneous clinical behavior, ranging from indolent to aggressive forms. Patients diagnosed with NETs usually receive a varied array of </span>treatments<span><span>, including somatostatin analogs<span>, locoregional treatments (ablation, intra-arterial therapy), cytotoxic chemotherapy, </span></span>peptide receptor </span></span>radionuclide therapy<span><span> (PRRT), and targeted therapies. To maximize therapeutic efficacy while limiting toxicity (both physical and economic), there is a need for accurate and reliable tools to monitor disease evolution and progression and to assess the effectiveness of these treatments. Imaging morphological methods, primarily relying on </span>computed tomography<span><span><span><span> (CT) and magnetic resonance imaging (MRI), are indispensable modalities for the initial evaluation and continuous monitoring of patients with NETs, therefore playing a pivotal role in gauging the response to treatment. The primary goal of assessing tumor response is to anticipate and weigh the benefits of treatments, especially in terms of survival gain. The World Health Organization took the pioneering step of introducing assessment criteria based on cross-sectional imaging. This initial proposal standardized the measurement of lesion sizes, laying the groundwork for subsequent criteria. The </span>Response Evaluation Criteria in Solid Tumors (RECIST) subsequently refined and enhanced these standards, swiftly gaining acceptance within the </span>oncology community. New treatments were progressively introduced, targeting specific features of NETs (such as </span>tumor vascularization<span> or expression of specific receptors), and achieving significant qualitative changes within tumors, although associated with minimal or paradoxical effects on tumor size. Several alternative criteria, adapted from those used in other cancer types and focusing on tumor viability, the slow growth of NETs, or refining the existing size-based RECIST criteria, have been proposed in NETs. This review article aims to describe and discuss the optimal utilization of CT and MRI for assessing the response of NETs to treatment; it provides a comprehensive overview of established and emerging criteria for evaluating tumor response, along with comparative analyses. </span></span></span></span>Molecular imaging will not be addressed here and is covered in a dedicated article within this special issue.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 5","pages":"Article 101827"},"PeriodicalIF":7.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms 神经内分泌肿瘤的酪氨酸激酶抑制剂和免疫治疗进展。
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-09-01 DOI: 10.1016/j.beem.2023.101796
Osama Mosalem (Hematology Oncology Fellow) , Mohamad Bassam Sonbol (Assisant Professor of Medicine) , Thorvardur R. Halfdanarson (Professor of Oncology) , Jason S. Starr (Assistant Professor of Medicine)

Neuroendocrine tumors (NETs) represent a heterogeneous group of malignancies that arise from neuroendocrine cells dispersed throughout the organs/tissues of the body. Treatment of advanced/metastatic disease varies depending on tumor origin and grade. Somatostatin analogs (SSA) have been the mainstay first-line treatment in the advanced/metastatic setting for tumor control and managing hormonal syndromes. Treatments beyond SSAs have expanded to include everolimus (mTOR inhibitor), tyrosine kinase inhibitors (TKI) (e.g., sunitinib), and peptide receptor radionuclide therapy (PRRT) with the choice of therapy to some extent dictated by the anatomic origin of the NETs. This review will focus on emerging systemic treatments for advanced/metastatic NETs, particularly TKIs, and immunotherapy.

神经内分泌肿瘤(NETs)是一组异质性恶性肿瘤,由分散在全身器官/组织中的神经内分泌细胞引起。晚期/转移性疾病的治疗因肿瘤来源和级别而异。生长抑素类似物(SSA)已成为晚期/转移性肿瘤控制和管理激素综合征的主要一线治疗方法。SSA以外的治疗已扩展到包括依维莫司(mTOR抑制剂)、酪氨酸激酶抑制剂(TKI)(如舒尼替尼)和肽受体放射性核素治疗(PRRT),在某种程度上,治疗的选择取决于NETs的解剖起源。这篇综述将集中于晚期/转移性NETs的新兴系统治疗,特别是TKIs和免疫疗法。
{"title":"Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms","authors":"Osama Mosalem (Hematology Oncology Fellow) ,&nbsp;Mohamad Bassam Sonbol (Assisant Professor of Medicine) ,&nbsp;Thorvardur R. Halfdanarson (Professor of Oncology) ,&nbsp;Jason S. Starr (Assistant Professor of Medicine)","doi":"10.1016/j.beem.2023.101796","DOIUrl":"10.1016/j.beem.2023.101796","url":null,"abstract":"<div><p><span>Neuroendocrine tumors (NETs) represent a heterogeneous group of </span>malignancies<span><span> that arise from neuroendocrine cells<span><span> dispersed throughout the organs/tissues of the body. Treatment of advanced/metastatic disease varies depending on tumor origin and grade. </span>Somatostatin analogs (SSA) have been the mainstay first-line treatment in the advanced/metastatic setting for tumor control and managing hormonal syndromes. Treatments beyond SSAs have expanded to include </span></span>everolimus<span><span> (mTOR inhibitor), tyrosine kinase inhibitors (TKI) (e.g., sunitinib), and </span>peptide receptor<span> radionuclide therapy<span> (PRRT) with the choice of therapy to some extent dictated by the anatomic origin of the NETs. This review will focus on emerging systemic treatments for advanced/metastatic NETs, particularly TKIs, and immunotherapy.</span></span></span></span></p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 5","pages":"Article 101796"},"PeriodicalIF":7.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9749489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Newly detected diabetes during the COVID-19 pandemic: What have we learnt? 新冠肺炎大流行期间新发现的糖尿病:我们学到了什么?
IF 7.4 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-07-01 DOI: 10.1016/j.beem.2023.101793
Dhruti Hirani (Internal Medicine Trainee) , Victoria Salem (Diabetologist & Diabetes UK Grand Challenge Senior Fellow) , Kamlesh Khunti (Professor of Primary Care Diabetes & Vascular Medicine) , Shivani Misra (Senior Clinical Lecturer & Wellcome Trust Career Development Fellow)

The SARS-CoV-2 pandemic has had an unprecedented effect on global health, mortality and healthcare provision. Diabetes has emerged as a key disease entity over the pandemic period, influencing outcomes from COVID-19 but also a tantalising hypothesis that the virus itself may be inducing diabetes. An uptick in diabetes cases over the pandemic has been noted for both type 1 diabetes (in children) and type 2 diabetes but understanding how this increase in incidence relates to the pandemic is challenging. It remains unclear whether indirect effects of the pandemic on behaviour, lifestyle and health have contributed to the increase; whether the virus itself has somehow mediated new-onset diabetes or whether other factors such as stress hyperglycaemic of steroid treatment during COVID-19 infection have played a roll. Within the myriad possibilities are some real challenges in interpreting epidemiological data, assigning diabetes type and understanding what in vitro data are telling us. In this review article we address the issue of newly-diagnosed diabetes during the pandemic, reviewing both epidemiological and basic science data and bringing together both strands of this emerging story.

严重急性呼吸系统综合征冠状病毒2型疫情对全球健康、死亡率和医疗保健产生了前所未有的影响。在大流行期间,糖尿病已成为一个关键的疾病实体,影响着新冠肺炎的结果,但也有一个诱人的假设,即病毒本身可能会诱导糖尿病。1型糖尿病(儿童)和2型糖尿病的糖尿病病例在疫情期间都有所增加,但了解发病率的增加与疫情的关系是一项挑战。目前尚不清楚疫情对行为、生活方式和健康的间接影响是否导致了这一增长;病毒本身是否以某种方式介导了新发糖尿病,或者新冠肺炎感染期间类固醇治疗的应激性高血糖等其他因素是否起了作用。在无数的可能性中,在解释流行病学数据、确定糖尿病类型和理解体外数据告诉我们的信息方面存在一些真正的挑战。在这篇综述文章中,我们讨论了疫情期间新诊断的糖尿病问题,回顾了流行病学和基础科学数据,并将这一新兴故事的两个方面结合起来。
{"title":"Newly detected diabetes during the COVID-19 pandemic: What have we learnt?","authors":"Dhruti Hirani (Internal Medicine Trainee) ,&nbsp;Victoria Salem (Diabetologist & Diabetes UK Grand Challenge Senior Fellow) ,&nbsp;Kamlesh Khunti (Professor of Primary Care Diabetes & Vascular Medicine) ,&nbsp;Shivani Misra (Senior Clinical Lecturer & Wellcome Trust Career Development Fellow)","doi":"10.1016/j.beem.2023.101793","DOIUrl":"10.1016/j.beem.2023.101793","url":null,"abstract":"<div><p>The SARS-CoV-2 pandemic has had an unprecedented effect on global health, mortality and healthcare provision. Diabetes has emerged as a key disease entity over the pandemic period, influencing outcomes from COVID-19 but also a tantalising hypothesis that the virus itself may be inducing diabetes. An uptick in diabetes cases over the pandemic has been noted for both type 1 diabetes (in children) and type 2 diabetes but understanding how this increase in incidence relates to the pandemic is challenging. It remains unclear whether indirect effects of the pandemic on behaviour, lifestyle and health have contributed to the increase; whether the virus itself has somehow mediated new-onset diabetes or whether other factors such as stress hyperglycaemic of steroid treatment during COVID-19 infection have played a roll. Within the myriad possibilities are some real challenges in interpreting epidemiological data, assigning diabetes type and understanding what in vitro data are telling us. In this review article we address the issue of newly-diagnosed diabetes during the pandemic, reviewing both epidemiological and basic science data and bringing together both strands of this emerging story.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 4","pages":"Article 101793"},"PeriodicalIF":7.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9918610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Best practice & research. Clinical endocrinology & metabolism
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1